Filters
-
Thema
-
Productvorm
-
Taal
-
Prijs
Resultaten voor 'oliver gassmann'
-
Führung und Organisation pharmazeutischer Innovation
Wie man den Wettlauf der Life Sciences gewinntDieses Buch untersucht und beleuchtet die wichtigsten Herausforderungen, denen sich die pharmazeutische Industrie in einem zunehmend wettbewerbsorientierten Umfeld mit inflationären F&E-Investitionen und verschärftem Kostendruck stellen muss.
€ 49,50 -
Patent Management
Protecting Intellectual Property and Innovation€ 71,50 -
Patent Management
Protecting Intellectual Property and Innovation€ 109,95 -
Leading Pharmaceutical Innovation
How to Win the Life Science RaceThis book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D; investments and tightening cost control pressures.
€ 71,50 -
Profiting from Innovation in China
China is dramatically catching up and is rapidly becoming a leading technological innovator on the global scale. The number of Chinese firms with global ambitions is growing fast, more and more technological innovation is coming from China, and the number of patents in China is also growing steadily.
€ 60,95 -
Profiting from Innovation in China
China is dramatically catching up and is rapidly becoming a leading technological innovator on the global scale. The number of Chinese firms with global ambitions is growing fast, more and more technological innovation is coming from China, and the number of patents in China is also growing steadily.
€ 62,50 -
Leading Pharmaceutical Innovation
This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D; investments and tightening cost control pressures. The authors present three sources of pharmaceutical innovation: new management methods in the drug development pipeline; new technologies as enablers for cutting-edge R&D; and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D.; New models and methods are illustrated with cases from Europe, the US, and Asia. This third fully revised edition was expanded to reflect the latest updates in open and collaborative innovation, the greater strategic importance of venture capital and early-stage investments, and the new range of emerging technologies now being put to use in pharmaceutical innovation.
€ 85,59